Several studies have recently confirmed that TNF inhibitors are effective in children with ERA (23), with reductions in inflammatory markers and pain, and better physical function, which is consistent with the current findings. The gene discussed is TNF; the disease is enthesitis-related juvenile idiopathic arthritis.